Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
'With our recently announced funding agreement in place, we are well positioned to continue advancing our lead clinical programs, CYB003 and CYB004, through multiple inflection points,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Gaining European CTA approval and MHRA approval to commence EMBRACE in the UK has enabled us to expand our multinational Phase 3 PARADIGM program evaluating CYB003 for the potential adjunctive treatment of major depressive disorder. PARADIGM is a significantly larger program than the completed Phase 2 study, with anticipated combined enrollment of approximately 550 participants. Our Phase 3 studies will evaluate the potential clinical benefits of CYB003 in patients living with moderate to severe MDD, and whose symptoms are uncontrolled with existing antidepressant treatment. Our Phase 2 study evaluating CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month.'
'Cybin is in a strong position to advance our programs and continue our work to deliver innovative therapies to address some of the most challenging mental health disorders we face today and is helping to build momentum across the sector - both from a clinical and regulatory perspective,' concluded Drysdale.
Recent Business and Pipeline Highlights:
Received European approval and MHRA approval for EMBRACE, the second Phase 3 study within the PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD, on schedule. The Company has received CTA approval from the Irish Medicines Board for the EMBRACE study in Ireland, Poland, and Greece, as well as approval from the MHRA. EMBRACE is a 12-week, randomized, double-blind, placebo-controlled study in 330 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but with inadequate response. EMBRACE will evaluate two doses of CYB003 (8 mg, 16 mg) three weeks apart, compared to an inactive placebo. The primary endpoint is change in depressive symptoms as measured by the change in MADRS from baseline six weeks after the first dose.
Making strong progress on CYB003 development through the APPROACH and EXTEND studies. Dosing is currently ongoing in the first pivotal study, APPROACH, which is expected to enroll 220 patients across 45 U.S. clinical sites. We are pleased to report that patient rollovers continue into EXTEND, the long-term extension study.
Clinical Program Summary
CYB003: Deuterated psilocin program
Phase 3 PARADIGM program is underway, with topline data from first pivotal study, APPROACH, expected in 2026 1.
CYB003 program accomplishments:
Received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD.
A completed Phase 2 study of CYB003 in MDD demonstrated durability of effect at 12 months:
100% of participants receiving two doses of 16 mg were responders.
71% of participants receiving two doses of 16 mg were in remission.
Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses.
CYB004: Deuterated dimethyltryptamine program
The Phase 2 CYB004 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with generalized anxiety disorder, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. Patient enrollment is expected to be completed this month 1.
Change in Presentation Currency
Effective April 1, 2025, the Company changed its presentation currency from the Canadian dollar to the United States dollar (' USD '). The change in presentation currency was made to better reflect the Company's operations, align with the currency in which the majority of cash-based expenses are denominated, and improve comparability of its financial results with other publicly traded businesses in the industry. As a result, all amounts presented in this press release are in USD unless otherwise stated.
First-Quarter Financial Highlights
Cash totaled $118.7 million as of June 30, 2025.
Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same period last year.
Cash-based operating expenses consisting of research, general, and administrative costs totaled $23.9 million for the quarter ended June 30, 2025, compared to $11.9 million, in the same period last year.
Cash flows used in operating activities were $29.5 million for the quarter ended June 30, 2025, compared to $19.9 million in the same period last year.
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Note:
There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; the Company's expectation to complete enrollment in CYB004 Phase 2 study in August 2025; the Company's expectation to receive topline data from APPROACH in 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
2 hours ago
- Time Magazine
Trump: No Business With Putin Until Ukraine War Is 'Settled'
President Donald Trump has offered the potential to resume business with Russia if they are able to make progress towards ending the war in Ukraine, signaling that renewed economic engagement between the U.S. and Russia could be on the horizon should peace negotiations yield tangible results. 'I noticed he's bringing a lot of business people from Russia, and that's good,' Trump told reporters aboard Air Force One en route to his meeting with Russian President Vladimir Putin in Alaska on Friday. 'I like that because they want to do business, but they're not doing business until we get the war settled.' The prospect of renewed business discussions comes after years of Russia's near-total estrangement from the global economy following its 2022 invasion of Ukraine, as sweeping sanctions and diplomatic pressure from the U.S., Europe, and allied nations have left Moscow largely isolated from major markets and financial systems. Read More: Why Trump's Summit in Alaska Cannot End Putin's War in Ukraine But Trump's suggestion that he might ease economic restrictions and resume business with Russia has drawn sharp criticism from European allies, who warn that any premature normalization could undermine the unified Western stance on sanctions and harm Ukraine's position in ongoing negotiations. Some analysts and Congressional Republicans, including Reps. Brian Fitzpatrick of Pennsylvania and Don Bacon of Nebraska, have also warned that such a move risks rewarding Putin's invasion by effectively legitimizing Russia's territorial gains and military aggression. When asked by TIME in the Oval Office on Thursday whether his peace incentives to Russia might inadvertently reward Putin and what message that could send to other potential aggressors, Trump responded: 'I don't see it as a reward.' The summit on Friday, which Trump referred to as 'high stakes,' marks the first face-to-face meeting between the two Presidents since 2019, with its outcome closely watched for any sign that the long-standing conflict may finally begin moving toward resolution. The talks will give Putin a chance to pitch his conditions for peace. The Kremlin has expressed its desire for Ukraine to hand over swaths of its territory—particularly areas in the south and east, which Putin's army has failed to fully occupy. Read More: Zelensky on Trump, Putin, and the Endgame in Ukraine Trump on Friday suggested he would not negotiate on behalf of Ukraine, particularly over whether to engage in territorial swaps with Russia. Ukrainian President Volodymyr Zelensky has repeatedly said he is not willing to cede any territory to Russia, insisting that such a move would 'gift their land to the occupier." European leaders have also warned that giving Russia land could embolden it to invade other countries. 'We are counting on America,' Zelensky said in a social media post on Friday. 'The key thing is that this meeting should open up a real path toward a just peace and a substantive discussion between leaders in a trilateral format—Ukraine, the United States, and the Russian side. It is time to end the war, and the necessary steps must be taken by Russia.' The summit will also give Putin the chance to appeal to Trump's business interests. Russia's Finance Minister Anton Siluanov and Kirill Dmitriev, a senior economic negotiator and head of Russia's sovereign wealth fund, are among those who accompanied Putin to Alaska. Asked if he would be discussing business opportunities with Russia during the meeting, Trump said: 'If we make progress, I would discuss it, because that's one of the things that they would like; they'd like to get a piece of what I built in terms of the economy.' Read More: The Secret White House Backchannel That Paved the Way For Trump's Summit With Putin It's unclear what kind of business deals Trump could use as leverage to resolve the war, but the President has previously threatened 'severe consequences' if Putin doesn't agree to end the conflict, including possible secondary sanctions on countries importing Russian oil and gas. Trump told reporters that he believes 'something' will come of the summit in Alaska and praised his relationship with Putin, whose invasion of Ukraine has resulted in tens of thousands of civilians killed and millions displaced. 'Look, he's a smart guy. Been doing it for a long time, but so have I. I've been doing it for a long time, and here we are. We're President[s],' Trump said on his way to the summit. 'We get along. There's a good respect level on both sides and I think something's going to come of it.'
Los Angeles Times
3 hours ago
- Los Angeles Times
Ethiopian fossil Lucy leaves for her first exhibition in Europe
ADDIS ABABA, Ethiopia — The human ancestor fossil known as Lucy left Ethiopia for display in a European museum, Ethiopian national media reported Friday, citing Tourism Minister Selamawit Kassa. Lucy's skeleton, which is 40% complete, left Ethiopia on Friday and will be displayed at the Czech National Museum in Prague for approximately two months. Lucy was recovered in Ethiopia in 1974 from what was an ancient lake near fossilized remains of crocodiles, turtle eggs and crab claws. She was a member of Australopithecus afarensis, an early human species that lived in Africa between about 4 million and 3 million years ago. This is the second time Lucy has left Ethiopia. The first was in 2013, when she toured the United States. Lucy's fragmented bones will be exhibited alongside Selam, the fossil of an Australopithecus baby that is about 100,000 years older than Lucy and was discovered in the same region 25 years later. 'As an iconic specimen, she belongs to the whole world, so sharing her with the rest of humanity is something that everyone would love to see,' said Yohannes Haile-Selassie, Director of the Institute of Human Origins at Arizona State University. While many experts believe Lucy's trip to Europe presents a once-in-a-lifetime opportunity for people in Europe and beyond, there are safety concerns about the transportation of her fragile bones. 'The fragmented bones of Lucy are truly unique and need utmost care. Traveling to Europe has its own risks,' said Gidey Gebreegziabher, an archaeologist and Ph.D. candidate at the University of Warsaw, Poland, 'She will also be exposed to different climate conditions, which could potentially have negative impacts on her preservation.' Even in Ethiopia, the public has only occasionally seen the real Lucy fossil. At the National Museum of Ethiopia, a replica of Lucy is exhibited while the actual remains are stored in a secure vault. 'I've seen how she was packed, so I have no worries about anything happening to Lucy anymore,' Yohannes said. Lucy's quiet departure on Thursday night also raises questions about transparency as many Ethiopians —who take pride in her — were unaware of her journey to Europe. 'It's unbelievable! The government appears to be deliberately sidelining its people from the narrative of their own heritage,' Gebreegziabher said. Bekele Reta, 43, a resident who lives just 164 feet from the museum where Lucy is housed, was unaware of Lucy's departure until he saw it on social media. 'I learned this morning on Facebook that Lucy has departed for Prague. It's unfortunate that most Ethiopians only have the opportunity to see her showcased elsewhere.' he said. Early this year, the director general of the Czech National Museum, Michal Lukeš, in a statement announcing the exhibition of Lucy and Selam, expressed his appreciation of the Ethiopians for agreeing to 'lend' the remains. 'These priceless exhibits give us a unique insight into the past and deepen our understanding of humanity's roots,' said Lukeš. Birhane writes for the Associated Press. AP writer Evelyne Musambi contributed to this report from Nairobi, Kenya.
Yahoo
3 hours ago
- Yahoo
Dollar Undercut by Decline in US Consumer Sentiment
The dollar index (DXY00) today is down -0.53%, undercut by today's weaker-than-expected US consumer sentiment report and today's -0.7 bp decline in the 2-year T-note yield. The dollar is also suffering from underlying foreign investor concern about the possibility of a politically-driven US monetary policy after US Treasury Secretary Bessent on Wednesday appeared to give the Fed marching orders on how much to cut interest rates. The markets are awaiting the outcome of this afternoon's Trump-Putin summit, which will begin at "around 3 pm ET" (11 AM Anchorage time), followed by a joint press conference, according to Reuters' description of the White House schedule. The outcome could have macroeconomic implications regarding tariffs and oil prices, and will, of course, have major implications for European security. More News from Barchart Dollar Sees Support from Strong US PPI Report Dollar Sees Support from Strong US PPI Report Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Today's headline US retail sales report was slightly weaker than market expectations, but there was an upward revision for June, leaving the report roughly neutral for the markets. The markets welcomed the report amidst worries about how US retail spending will hold up with a weaker labor market and consumer uncertainty about inflation and the economic outlook. July US retail sales rose +0.5% m/m, slightly weaker than market expectations of +0.6%, although June was revised higher to +0.9% from +0.6%. July retail sales ex-autos rose +0.3% m/m, in line with market expectations and down from June's revised +0.8% (preliminary +0.5%). The University of Michigan's preliminary-Aug US consumer sentiment index fell by -3.1 points to 58.6, which was weaker than expectations for a slight +0.3 point increase to 62.0. The survey showed that US consumer expectations for inflation rose to +4.9% over the next year and to an annual +3.9% for the next 5-10 years. The survey also found that 58% of consumers plan to cut spending due to inflation. July US import prices rose +0.4% m/m, which was stronger than expectations of +0.1%. On a year-on-year basis, July US import prices strengthened to -0.2% from a revised -0.5% y/y in June. July US import prices ex-petroleum rose +0.3% m/m versus June's revised -0.2% (preliminary unchanged). Today's July US industrial production report of -0.1% m/m was slightly weaker than expectations of unchanged, although June was revised upward to +0.4% m/m from +0.3%. July manufacturing production was unchanged m/m, matching market expectations, while July was revised higher to +0.3% from +0.1%. Today's Aug Empire manufacturing index of 11.9 was substantially stronger than market expectations of zero and was up from July's 5.5. Chicago Fed President Austan Goolsbee delivered mildly hawkish remarks today, stating that he would like to see at least one more inflation report to ensure that persistent inflation pressures aren't emerging. He expressed concern about the high service inflation data in the July CPI report, but noted the importance of not placing too much weight on a single month's data. The markets today will continue to adjust to the inflation outlook following Thursday's hawkish PPI report. The July final-demand PPI surged to +3.3% y/y (nominal) and +3.7% y/y (core). The PPI report suggested that the markets were overly optimistic about Tuesday's CPI report and that companies are passing through tariffs at the wholesale level at a higher pace than earlier thought. Following the report, the markets erased any hopes of a -50 bp rate cut at the Fed's September meeting and pulled back expectations for a -25 bp rate cut to 93% from 100% before the report. Weak Chinese economic reports overnight were negative for the global economic growth outlook. China's economy is weakening due to US tariffs and the Chinese government's attempt to crack down on excessive competition that has driven prices to loss-making levels in some industries. China's July retail sales report of +3.7% y/y was weaker than expectations of +4.6% and down from June's +4.8%. China's July industrial production report of +5.7% y/y was weaker than expectations of +6.0% and was down from June's +6.8%. China's July jobless rate rose to 5.2% from June's +5.0% and was higher than expectations. China's July property investment fell -12.0% ytd y/y from -11.2% in June and was weaker than expectations of -11.4%. In recent tariff news, President Trump early Tuesday extended the tariff truce with China for another 90 days until November. Last Wednesday, Mr. Trump announced that he will impose a 100% tariff on semiconductor imports. Still, companies would be eligible for exemptions if they demonstrate a commitment to building their products in the US. However, the US will levy a separate tax on imports of electronic products that employ semiconductors. Also, Mr. Trump announced last Wednesday that he will double tariffs on US imports from India to 50% from the current 25% tariff, due to India's purchases of Russian oil. Last Tuesday, Mr. Trump said that US tariffs on pharmaceutical imports would be announced "within the next week or so." According to Bloomberg Economics, the average US tariff will rise to 15.2% if rates are implemented as announced, up from 13.3% earlier, and significantly higher than the 2.3% in 2024 before the tariffs were announced. Federal funds futures prices are discounting the chances for a -25 bp rate cut at 93% at the September 16-17 FOMC meeting and at 53% for a second -25 bp rate cut at the following meeting on October 28-29. EUR/USD (^EURUSD) is up +0.58% on dollar weakness. The euro has some underlying support from hopes of some progress on ending the Russia-Ukraine war at today's Trump-Putin summit. Swaps are pricing in a 5% chance of a -25 bp rate cut by the ECB at the September 11 policy meeting. USD/JPY (^USDJPY) is down -0.63% due to weakness in the dollar. The yen saw some underlying support after US Treasury Secretary Bessent earlier this week said the Bank of Japan is falling behind the curve in addressing inflation and that he expects a rate hike. However, the yen continues to be undercut by concern that US tariff policies will harm the Japanese economy. December gold (GCZ25) is up +5.7 (+0.17%), and September silver (SIU25) is down -0.124 (-0.33%). Gold is seeing support today from the weaker dollar. Silver is seeing weakness on concern about industrial metals demand after today's weaker-than-expected US consumer sentiment index and Chinese economic data. Gold continues to have safe-haven support related to US tariffs and geopolitical risks, including the conflicts in Ukraine and the Middle East. Fund buying of precious metals continues to support prices after gold holdings in ETFs rose to a 2-year high on Tuesday, and silver holdings in ETFs reached a 3-year high last Friday. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
